~~<i id='95BECD8647'><strike id='95BECD8647'><tt id='95BECD8647'><pre id='95BECD8647'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：hotspot 2025-08-26 23:48:10 - browse：79245

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： What to make of Biden’s latest efforts on cancer research

hotspot

leisure time

entertainment

leisure time

knowledge

focus

PresidentBidenspeaksontheCancerMoonshotinitiativeattheJohnF.KennedyLibraryin2022.EvanVucci/APWASHING

WSS

Hospitals consider fixing cancer drug shortages on their own

WATCH: Why do bright lights make us see spots?

Akili, maker of video game for ADHD, to be acquired for 34 million

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

David Sabatini, ex

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

focus

fashion

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

WATCH: Why do bright lights make us see spots?

Medical leaders decry Supreme Court decision on affirmative action

Walmart eyes Medicare Advantage provider ChenMed

Medical leaders decry Supreme Court decision on affirmative action

How medical schools plan to diversify without affirmative action

23andMe had bad news about my health. I wish a person had delivered it

Akili, maker of video game for ADHD, to be acquired for 34 million

In age of alternative facts, a scholarly course on calling out crap

Report: NIH

leisure time

Will the IRA bring competition to the biologics market?

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Lab trade group sues FDA to halt regulation of lab

Focused ultrasound for uterine fibroids: an uphill battle

Report: NIH

AI used to predict Covid

entertainment

leisure time

knowledge

focus